Genzyme (GENZ) Valued at $20B by Sanofi Aventis; Deal Could Happen Within a Week
Tweet Send to a Friend
Sanofi Aventis SA has valued Genzyme Corp. (NASDAQ: GENZ) at about $76-$77 per share, or roughly $20 billion, which includes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
